Top Markets
Coin of the day
Aeglea BioTherapeutics, Inc. Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc.

AGLE
Classement en actions #23495
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated... Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Prix de l'action
$19.30
Dernière synchronisation: 2023-12-26
Capitalisation boursière
$72.77M
Changement (1 jour)
6.22%
Changement (1 an)
0.00%
Pays
US
Échange Aeglea BioTherapeutics, Inc. (AGLE)

Catégorie

Historique du rendement du dividende pour Aeglea BioTherapeutics, Inc. (AGLE)
Le rendement du dividende (TTM) de Aeglea BioTherapeutics, Inc. (symbole boursier : AGLE) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Aeglea BioTherapeutics, Inc. (AGLE) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH